CN120418354A - 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法 - Google Patents
含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法Info
- Publication number
- CN120418354A CN120418354A CN202380088606.2A CN202380088606A CN120418354A CN 120418354 A CN120418354 A CN 120418354A CN 202380088606 A CN202380088606 A CN 202380088606A CN 120418354 A CN120418354 A CN 120418354A
- Authority
- CN
- China
- Prior art keywords
- solid dispersion
- less
- polymer
- dispersed
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
- C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/32—Cellulose ether-esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-211372 | 2022-12-28 | ||
| JP2022211372 | 2022-12-28 | ||
| PCT/JP2023/047077 WO2024143501A1 (ja) | 2022-12-28 | 2023-12-27 | 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120418354A true CN120418354A (zh) | 2025-08-01 |
Family
ID=91717899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380088606.2A Pending CN120418354A (zh) | 2022-12-28 | 2023-12-27 | 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4603546A1 (https=) |
| JP (1) | JPWO2024143501A1 (https=) |
| CN (1) | CN120418354A (https=) |
| TW (1) | TW202440065A (https=) |
| WO (1) | WO2024143501A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60038097T2 (de) * | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| TNSN03137A1 (en) | 2001-06-22 | 2005-12-23 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS. |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| HRP20041152B1 (hr) * | 2002-05-07 | 2008-01-31 | Ferring B.V. | Farmaceutske formulacije |
| DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| US8372836B2 (en) | 2006-10-17 | 2013-02-12 | Bend Research, Inc. | Spray dried formulation |
| ES2525353T3 (es) | 2009-04-28 | 2014-12-22 | Chugai Seiyaku Kabushiki Kaisha | Derivado de espiroimidazolona |
| CA2892621C (en) | 2012-12-10 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | Hydantoin derivative |
| MX375448B (es) * | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| EP3153166B1 (en) | 2014-06-09 | 2022-08-03 | Chugai Seiyaku Kabushiki Kaisha | Hydantoin derivative-containing pharmaceutical composition |
| WO2016031651A1 (ja) * | 2014-08-29 | 2016-03-03 | 花王株式会社 | 難溶解性ポリフェノール類を含有する固体分散体の製造方法 |
| US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
| CA3095036A1 (en) * | 2018-03-23 | 2019-09-26 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
-
2023
- 2023-12-27 JP JP2024567955A patent/JPWO2024143501A1/ja active Pending
- 2023-12-27 WO PCT/JP2023/047077 patent/WO2024143501A1/ja not_active Ceased
- 2023-12-27 CN CN202380088606.2A patent/CN120418354A/zh active Pending
- 2023-12-27 EP EP23912278.1A patent/EP4603546A1/en active Pending
- 2023-12-27 TW TW112151142A patent/TW202440065A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024143501A1 (ja) | 2024-07-04 |
| EP4603546A1 (en) | 2025-08-20 |
| TW202440065A (zh) | 2024-10-16 |
| JPWO2024143501A1 (https=) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2454220C2 (ru) | Способ получения твердых дисперсий высококристаллических терапевтических соединений | |
| RU2713428C1 (ru) | Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат | |
| KR101374854B1 (ko) | 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법 | |
| JP2011530532A5 (ja) | 固体分子分散物状のｈｃｖプロテアーゼインヒビターの薬学的処方物 | |
| WO2009121871A1 (en) | Pharmaceutical composition comprising candesartan | |
| ES3055123T3 (en) | Pharmaceutical composition comprising enzalutamide | |
| IE59540B1 (en) | Sustained release capsule or tablet formulation | |
| US20150064252A1 (en) | Solid dispersion formulation of an antiviral compound | |
| WO2023220112A1 (en) | Glp1 tablet compositions | |
| JP2020529464A (ja) | ３−フルオロ−４−［７−メトキシ−３−メチル−８−（１−メチル−１Ｈ−ピラゾール−４−イル）−２−オキソ−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル］−ベンゾニトリル含む医薬製剤 | |
| CN120418354A (zh) | 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法 | |
| KR101441450B1 (ko) | 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도 | |
| WO2019192195A1 (zh) | 含达比加群酯的药物组合物及其制备方法 | |
| EP3644970A1 (en) | New oral formulations of belinostat | |
| WO2024171019A1 (en) | Pharmaceutical composition of trametinib and process of preparation thereof | |
| TW202019416A (zh) | 乙內醯脲衍生物的固體分散體 | |
| JP7657201B2 (ja) | 直鎖ポリ（アクリル酸）ポリマーを使用した薬物－ポリマーアモルファス固体分散体 | |
| WO2019002614A1 (en) | NEW ORAL FORMULATIONS OF BELINOSTAT | |
| US20170143678A1 (en) | Pharmaceutical composition for oral administration | |
| CA3206841A1 (en) | Amorphous solid dispersion formulation | |
| WO2020122244A1 (ja) | 錠剤及びその製造方法 | |
| WO2025220686A1 (ja) | ペプチド、糖脂肪酸エステル構造を有する界面活性剤及び（メタ）アクリル酸系ポリマーを含む医薬組成物 | |
| TW201805003A (zh) | Bcl-2抑制劑之醫藥固體分散物、其醫藥組合物及用於治療癌症之用途 | |
| WO2025229513A1 (en) | Pharmaceutical composition of resmetirom and process thereof | |
| HK40115112A (zh) | 包含帽依赖性核酸内切酶抑制剂的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40122238 Country of ref document: HK |